Vesugen
Khavinson vascular tripeptide (Lys-Glu-Asp, KED)
Overview
Vesugen is a Khavinson-class tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), positioned within the Khavinson framework as the vascular endothelial regulatory peptide. The KED sequence is distinct from the tetrapeptide-family members (AEDG / AEDL / AEDP) in that it is a three-residue rather than four-residue peptide and includes a basic N-terminal lysine, both features shifting its biophysical profile from the AEDx tetrapeptide siblings. Vesugen is studied in research workflows examining vascular endothelial gene-expression programs, angiogenesis-related signaling, and cardiovascular tissue maintenance within the Khavinson bioregulator framework. Lyochem supplies Vesugen as a lyophilized 10 mg vial at ≥99.0% HPLC purity. As a tripeptide, Vesugen is simpler analytically than the tetrapeptide siblings, the molecular weight (392 g/mol theoretical) is distinct from the AEDx tetrapeptide family and mass-spec confirmation alone is generally sufficient for identity. Sequence verification by LC-MS/MS is available on request.
Who buys this, and why
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- (verification pending, please confirm via COA)
- Sequence
- KED
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 10 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Source-literature pointer (Russian-language references on request)
- Stability at −20 °C across 12 months
- Sequence ladder available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm KED sequence and identity per batch COA.
Frequently asked questions
How is Vesugen different from the AEDx Khavinson tetrapeptides?▾
Vesugen (KED, Lys-Glu-Asp) is a tripeptide, while the more commonly characterized Khavinson family members (Epitalon AEDG, Bronchogen AEDL, Cortagen AEDP) are tetrapeptides. The size difference produces biophysical and analytical differences: Vesugen at 392 g/mol is distinct in mass from the tetrapeptide family (390-432 g/mol), so mass spec alone is sufficient for identity disambiguation against the tetrapeptides. The N-terminal lysine also gives Vesugen a different charge profile than the AEDx tetrapeptides (which start with neutral alanine), affecting RP-HPLC retention time. Vesugen is positioned within the Khavinson framework as the vascular endothelial regulatory peptide, mechanistically and tissue-targeting-wise distinct from its cousin peptides.
What's the published research context for vascular-endothelial regulatory peptides in the Khavinson framework?▾
Russian-school publications on Vesugen and similar vascular-targeting short peptides focus on age-related endothelial dysfunction and atherosclerosis-prevention research in animal models. The mechanism hypothesis within the Khavinson framework is that the KED tripeptide acts as a regulatory signal on endothelial gene-expression programs, supporting vascular homeostasis and counteracting age-related decline in endothelial-cell turnover. Reported readouts in published studies include modulation of endothelial-cell proliferation markers, vasodilation-relevant gene expression, and improvements in vascular-function metrics in aged-rodent models. As with the broader Khavinson framework, the evidence base is concentrated in Russian-language journals; Western independent replication is limited, and Vesugen should be treated as an investigational research tool rather than a validated vascular therapeutic.
What's the recommended aliquoting and storage approach for the Vesugen tripeptide?▾
Lyophilized Vesugen is stable at -20 °C protected from light for the standard 24-month re-test window. The KED sequence is short (3 residues) and the N-terminal lysine makes the molecule somewhat more soluble in aqueous media than the more hydrophobic AEDx tetrapeptides, reconstitution in isotonic saline or sterile water for injection produces a clean solution at typical 1-5 mg/mL working concentrations. The reconstituted solution should be split into single-use aliquots immediately and frozen at -20 °C; as with all short Khavinson peptides, freeze-thaw cycling is the dominant in-lab degradation pathway. The 10 mg standard fill supports 50-200 single-dose research preparations depending on the protocol-specified dose per administration.